Related Experiment Videos
In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents
M E Shapiro1, R L Kirkman, V R Kelley
1Beth Israel Hospital, Boston, Massachusetts.
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The use of executed prisoners as a source of organ transplants in China must stop.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis.
Journal of the American Academy of Dermatology·2001
Flavin specificity and subunit interaction of Vibrio fischeri general NAD(P)H-flavin oxidoreductase FRG/FRase I.
Archives of biochemistry and biophysics·2001
Interferon-alpha 2a treatment of neuro-Behcet disease.
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2001
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Molecular cloning of ricin.
Targeted diagnosis and therapy·1992
Severe perioperative immune-related adverse events requiring intensive care in patients with gastric cancer: a case series.
Journal of medical case reports·2026
Ileorectal fistula after resection of perforated sigmoid tumor and Hartmann's procedure with uterine invasion: a case report.
Journal of medical case reports·2026
[Intravenous Thrombolysis for Acute Ischemic Stroke: Current Evidence and Perspectives].
No shinkei geka. Neurological surgery·2026
The Effectiveness of Emotion Regulation-Based Therapy on Emotion Regulation, Cognitive Flexibility, and Symptom Severity in Patients with Irritable Bowel Syndrome.
Clinics and research in hepatology and gastroenterology·2026
Mechanistic basis for the selective recognition of the Fcγ receptor IIa by monoclonal antibody IV.3.
Journal of structural biology·2026